WILMINGTON, DE — Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when followed by paclitaxel, trastuzumab, and pertuzumab ...

AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed significant improvement as a first line treatment of metastatic breast cancer ...

Taking a closer look at the design of the 58-subject study, half received Enhertu solo, while another 29 were given Enhertu plus the hormone treatment anastrozole. Patients were further broken ...

Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings ...

Cancer drug history was made last Friday. Enhertu, the blockbuster antibody-drug conjugate discovered by Daiichi Sankyo and co-developed by AstraZeneca, was approved in the U.S. to treat any ...

Enhertu plus Perjeta showed significant improvement in progression-free survival in HER2-positive metastatic breast cancer patients compared to standard treatment. The DESTINY-Breast09 trial is the ...

Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s ENHERTU that showed clinically meaningful responses across a broad range of tumors ENHERTU now has five approved indications ...

In 2019 it formed a partnership with AstraZeneca to co-develop and co-commercialize Enhertu and Dato-DXd ... and insight into ADC chemistry and design. Although ADCs have been in existence ...

The FDA has said AstraZeneca and Daiichi Sankyo’s Enhertu could be a breakthrough in a potential new lung cancer niche, the second time in the space of a week that the drug has received ...

Get Instant Summarized Text (Gist) Trastuzumab deruxtecan, known as Enhertu, has been approved in the UK for treating advanced HER2-positive cancers that are inoperable or have metastasized. This ...